Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer
Information source: Roger Williams Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Lung Cancer
Intervention: EGFRBi-armed autologous activated T cells (Biological); aldesleukin (Biological); sargramostim (Biological)
Phase: Phase 1
Status: Terminated
Sponsored by: Roger Williams Medical Center Official(s) and/or principal investigator(s): Abby Maizel, MD, PhD, Study Chair, Affiliation: Roger Williams Medical Center
Summary
RATIONALE: Giving autologous lymphocytes that have been treated in the laboratory with
antibodies may stimulate the immune system to kill tumor cells. Aldesleukin may stimulate
the lymphocytes to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may
increase the number of immune cells found in bone marrow or peripheral blood. Giving
laboratory-treated autologous lymphocytes together with aldesleukin and GM-CSF may kill more
tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of laboratory-treated
autologous lymphocytes when given together with aldesleukin and GM-CSF in treating patients
with recurrent, refractory, or metastatic non-small cell lung cancer.
FUNDING SOURCE--FDA OOPD
Clinical Details
Official title: A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung Cancer
Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: SafetyMaximum tolerated dose of EGFRBi-armed autologous activated T-cells Determination of immunologic changes by evaluation of cytokine profiles obtained before and after stimulation with OKT3 in vitro
Secondary outcome: Overall survivalProgression-free survival Evaluation of tumor markers and human anti-mouse antibody responses as assessed by carcinoembryonic antigen (CEA) levels in serum samples and development of IgG and IgM anti-mouse antibody responses to the Bi-antibodies Determination of immunologic changes by evaluation of peripheral blood lymphocytes Determination of immunologic changes by evaluation of cytotoxic T-lymphocytes as measured by interferon gamma ELISPOTS directed at autologous tumor or lung cancer cell lines Determination of immunologic changes by evaluation of phenotypes of peripheral blood mononuclear cells before and after immunotherapy
Detailed description:
OBJECTIVES:
Primary
- Determine the safety and maximum tolerated dose of EGFRBi-armed autologous activated
T-cells (ATC) when administered in combination with low-dose aldesleukin and
sargramostim (GM-CSF) in patients with recurrent, refractory, or extensive (metastatic)
non-small cell lung cancer (NSCLC).
Secondary
- Assess clinical outcome based on tumor responses, overall survival, and
progression-free survival.
- Monitor changes in sera concentrations of the tumor marker in association with
EGFRBi-armed ATC administration throughout the study and at time points thereafter in
patients with elevated levels of carcinoembryonic antigen (CEA) prior to beginning the
study.
- Monitor patient sera for human anti-mouse antibodies (HAMA).
- Evaluate immune response, which may reflect immune augmentation in response to
EGFRBi-armed ATC infusions, in peripheral blood mononuclear cell (PBMC) samples as well
as purified immune cell populations.
- Investigate proliferation in response to ex vivo stimulation with NSCLC
tumor-associated antigens, sera cytokine profiles (Th1 vs Th2), cytotoxicity of patient
PBMC, and interferon gamma ELISPOTS as a surrogate marker for assessing generation of
EGFR-specific cytotoxic T-lymphocytes (CTL).
OUTLINE: Peripheral blood mononuclear cells (PBMCs) are collected by 1 or 2 leukaphereses
for the generation of activated T cells (ATCs). The PBMCs are activated with OKT3 (anti-CD3)
and expanded in aldesleukin for up to 14 days. The ATCs are then armed with EGFRBi.
Patients receive EGFRBi-armed autologous ATCs IV over 30-60 minutes twice weekly for 4 weeks
(a total of 8 infusions) in the absence of disease progression or unacceptable toxicity.
Patients also receive low-dose aldesleukin subcutaneously (SC) once daily and sargramostim
(GM-CSF) SC twice weekly beginning 3 days before the first ATC infusion and continuing for 1
week after the last ATC infusion.
After completion of study therapy, patients are followed periodically.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
- Recurrent, refractory, or metastatic disease after ≥ 1 prior first-line regimen
(chemotherapy or radiotherapy)
- Documented EGFR-positive disease (any expression level) by immunohistochemistry (IHC)
(may be based on archival sample)
- Measurable or evaluable disease by radiograph, CT scan, MRI, and/or physical exam
- Appropriate slides of the primary lesion must be available for review of IHC staining
assessment by a central pathology team
- No clinical evidence of active brain metastases
- Patients with brain metastases are eligible provide they have received
definitive radiotherapy or chemotherapy and/or have undergone surgical resection
for brain metastases
- No prior hematological malignancy
PATIENT CHARACTERISTICS:
- Karnofsky performance status (PS) 60-100% OR ECOG PS 0-2
- Life expectancy ≥ 3 months
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Granulocytes ≥ 1,000/mm^3
- Platelet count ≥ 50,000/mm^3
- Hemoglobin ≥ 8 g/dL
- BUN ≤ 2. 0 times normal
- Serum creatinine ≤ 2. 0 mg/dL
- Bilirubin ≤ 1. 5 times normal
- SGOT ≤ 1. 5 times normal (with or without liver metastases)
- Hepatitis B surface antigen and HIV negative
- LVEF ≥ 45 % at rest (by MUGA)
- No evidence of depressed left ventricular function
- FEV_1, DLCO, and FVC ≥ 50% of the predicted value
- No other malignancy, except for the following:
- History of curatively treated in situ squamous cell carcinoma or basal cell
carcinoma of the skin
- History of other curatively treated malignancy (except those with a hematologic
origin) for which the patient has remained in complete remission > 5 years after
completing therapy (as documented by history, physical exams, tumor markers, and
radiology scanning)
- No serious medical or psychiatric illness that would preclude giving informed consent
or receiving intensive treatment
- No recent myocardial infarction (within the past year)
- No current angina/coronary symptoms requiring medications
- No clinical evidence of congestive heart failure requiring medical management
(irrespective of MUGA results)
- No systolic blood pressure (BP) ≥ 130 mm Hg or diastolic BP ≥ 80 mm Hg
- Patients with elevated BP must have it controlled by anti-hypertensive
medications for at least 7 days prior to the first infusion
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 4 weeks since prior chemotherapy or radiotherapy
- At least 4 weeks since prior cetuximab or small molecule EGFR-inhibitors including,
but not limited to, gefitinib or erlotinib hydrochloride
- No concurrent radiotherapy
- No concurrent steroids except for treatment of adrenal failure, septic shock, or
pulmonary toxicity or hormones for non-disease-related conditions (e. g., insulin for
diabetes)
Locations and Contacts
Roger Williams Medical Center, Providence, Rhode Island 02908-4735, United States
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: November 2007
Last updated: March 24, 2015
|